10th International Congress on Drug Therapy in HIV Infection, November 7-11, 2010, Glasgow

Conference Reports for NATAP


10th International Congress on Drug Therapy in HIV Infection November 7-11, 2010 Glasgow, Scotland

	Assessing the Risks of Birth Defects Associated With Atazanavir Exposure in Pregnancy - (12/22/10) Nevirapine Versus Ritonavir-Boosted Atazanavir CombinedWith Tenofovir/ Emtricitabine in First-LineTherapy: NEWART 48-Week Data - (12/05/10) Analysis of BENCHMRK-1&2 Using PhenoSense Assay for Darunavir (DRV/r) Resistance and Exploration of Functional Monotherapy with RAL vs DRV - (11/29/10) 48 Wk Efficacy and Safety of Switching Virologically Stable HIV-1 Patients from Nevirapine IR 200 mg BID to Nevirapine XR 400 mg QD (TRANxITION) (2) - (11/22/10) 48 Wk Efficacy and Safety of Switching Virologically Stable HIV-1 Patients from Nevirapine IR 200 mg BID to Nevirapine XR 400 mg QD (TRANxITION) - (11/18/10) Population and Ultra-Deep Sequencing for Tropism Determination Are Correlated With Trofile-ES. Genotypic Re-Analysis of the A4001078 Maraviroc Study - (11/18/10) No effect of a single supratherapeutic dose of lersivirine, a next-generation NNRTI, on QTc interval in healthy subjects - (11/18/10) The 10-Year Safety and Efficacy of Tenofovir DF (TDF)-Containing HAART in Antiretroviral Naïve Patients - (11/18/10) Adherence to Antiretroviral Treatment Regimens and Correlation with Risk of Hospitalization Among Commercially Insured HIV Patients in the United States - (11/18/10) The 5 Year Safety and Efficacy of the Once-Daily Antiretroviral-Naïve Patient Regimen of Efavirenz (EFV)/Emtricitabine (FTC)/Tenofovir DF (TDF) - (11/18/10) Adherence to Antiretroviral Treatment Regimens and Correlation with Risk of Hospitalization Among Commercially Insured HIV Patients in the United States - (11/18/10) Switching to Atripla (EFV/FTC/TDF) from Kivexa (ABC/3TC) Plus EFV Leads to Improved Perceptions of Treatment: Results from the ROCKET 1 Study - (11/18/10) New Nonnucleoside Retains Activity Against Some Virus Resistant to Etravirine - (11/18/10) Activity of Integrase Inhibitor, S/GSK1349572 in Subjects with HIV Exhibiting Raltegravir Resistance: Week 24 Results of VIKING Study (ING112961) - (11/17/10) PK/PD Modeling Supports Dose Escalation Decision in VIKING (50 mg twice-daily for highly raltegravir resistant patients) - (11/17/10) Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile (activity vs etravirine resistance) - (11/17/10) Influence of Amount and Percentage of CXCR4-Using Virus in Predicting Week 48 Responses to Maraviroc, Zidovudine and Lamivudine (CBV) in Treatment-Naive Patients - (11/17/10) Influence of Amount and Percentage of CXCR4-Using Virus in Predicting Week 48 Responses to Maraviroc in Treatment-Naive Patients - (11/17/10) Once-Daily S/GSK1349572 Combination Therapy in Antiretroviral-Naïve Adults: Rapod and Potent 24-Week Antiviral Responses on SPRING-1 Antiviral Responses - (11/17/10) The SENSE trial: Etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients - (11/16/10) Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE - (11/16/10) Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the Phase III ECHO and THRIVE trials - (11/16/10) Neuropscyh Side Effect Rate Lower With Etravirine Than Efavirenz at 12 Weeks - Written by Mark Mascolini - (11/15/10) METABOLIK: Week 48 Comparison of Metabolic Parameters and Biomarkers in Subjects Receiving Darunavir/ritonavir or Atazanavir/ritonavir - (11/15/10) Switching from Kivexa (KVX) + Efavirenz (EFV) to Atripla (ATR) Reduces Total Cholesterol in Hypercholesterolemic Subjects: Final Results of a 24-week, Randomised Study - (11/15/10) Pooled Week 48 safety and efficacy results from the ECHO and THRIVE Phase III trials comparing TMC278 vs efavirenz in treatment-naïve HIV-1-infected patients - (11/15/10) European Panel Recommends Either Geno (g2p) or Pheno (ESTA) for Tropism Testing - Written by Mark Mascolini - (11/12/10) New S/GSK Integrase Inhibitor Looks Good at 24 Weeks in Phase 2 Trial - Written by Mark Mascolini - (11/12/10) Higher AIDS and non-AIDS Rates With Uncontrolled HIV Despite CD4s Over 350 - Written by Mark Mascolini - (11/12/10) Major and Minor PI Mutations in MONET Darunavir Monotherapy Trial - Written by Mark Mascolini - (11/12/10) Vitamin D Deficiency in EuroSIDA Linked to All-Cause Mortality and AIDS - Written by Mark Mascolini - (11/12/10) Long-Term T-cell Changes With Maraviroc in Four Randomized Trials - Written by Mark Mascolini - (11/12/10) Adding Maraviroc Does Not Boost CD4s in Randomized Trial - Written by Mark Mascolini - (11/12/10) Pretreatment Coreceptor Preference Affects Virologic Response in Naive - Written by Mark Mascolini - (11/12/10) Atazanavir/RTV Stopped Less Than Other Key First-Line Drug in Large French Analysis - Written by Mark Mascolini - (11/12/10) Muscle Weakness or Pain Analyzed as Possible Raltegravir Side Effect - Written by Mark Mascolini - (11/12/10) Switch to Twice-Daily Unboosted Atazanavir Outdoes Switch to Once-Daily Dose - Written by Mark Mascolini - (11/12/10) Switching From ABC/3TC to TDF/FTC Cuts Lipids in Randomized Trial - Written by Mark Mascolini - (11/12/10) Dual Combo of Darunavir/Ritonavir and Etravirine Assessed in London Clinic - Written by Mark Mascolini - (11/10/10) NRTI Exposure Tied to Age-Linked Mitochondrial DNA Deletions - Written by Mark Mascolini - (11/10/10) Anemia in SMART Study Tied to Risk of non-AIDS Disease and Death - Written by Mark Mascolini - (11/10/10) Vitamin D Deficiency in HCV/HIV-Coinfected People in the UK - Written by Mark Mascolini - (11/10/10) Differing HCV Response Rates Depending on HIV in Prospective German Cohort - Written by Mark Mascolini - (11/10/10) Extensive Three-Class Resistance May No Longer Predict Progression or Death - Written by Mark Mascolini - (11/09/10) Darunavir Mutation Rate Dropping in Large Clinical Sample Survey - Written by Mark Mascolini - (11/09/10) More Drugs in Regimen--Not Just More Pills--Hurt Adherence - Written by Mark Mascolini - (11/09/10) PI MONOTHERAPY - Darunavir Monotherapy Equivalent to Triple Therapy in Meta-Analysis - Written by Mark Mascolini - (11/09/10) Switch From Suppressive PI to Abacavir Combo Not Effective in French Cohort Study - Written by Mark Mascolini - (11/09/10) Small But Significant CD4 Gains When Switching Antiretrovirals With Sub-50 Load - Written by Mark Mascolini - (11/09/10) One Third in Large UK HIV Survey Have Fractures, 14% of Them Osteoporotic - Written by Mark Mascolini - (11/09/10) Lifetime Spine Fracture Risk Greater With Than Without HIV in UK Comparison - Written by Mark Mascolini - (11/08/10) Long-Term Resistance Rate Low When Starting ART Within Year of HIV Diagnosis - Written by Mark Mascolini - (11/08/10) Good Adherence Lowers Hospital Risk 40% in Insured US Patients With HIV - Written by Mark Mascolini - (11/08/10)